业绩持续下滑的深层动因 2024年，华恒生物净利润大幅缩水的主因在于缬氨酸产品的价格压力。公司明确表示，"2024年市场缬 氨酸产品价格处于历史低位"，且"市场竞争加剧"导致该产品价格及毛利率同比显著下降。作为氨基酸 系列的核心品类之一，缬氨酸的价格波动直接冲击了公司利润空间。此外，经营规模扩大带来的费用增 加进一步侵蚀利润，2024年相关费用较去年同期明显攀升。 作为合成生物领域的龙头企业，华恒生物近年来的业绩表现与股价走势引发市场高度关注。2024年，公 司营业收入虽同比增长12.37%至21.78亿元，但归母净利润同比暴跌57.80%至1.9亿元，扣非净利润下滑 59.54%至1.77亿元。2025年一季度，其营收增长37.20%至6.87亿元，但归母净利润同比下降40.98%至 5109.61万元，连续四个季度呈现负增长态势。面对市场竞争加剧与核心产品价格承压的双重挑战，华 恒生物正通过高管团队调整与技术布局寻求突围。 2025年一季度，尽管销售规模扩大推动营收增长，但净利润下滑趋势仍未扭转。公司解释称，"缬氨酸 产品价格及毛利率较去年同期下降"是核心影响因素。若行业竞争格局维持现状或进一步恶化，华恒 ...

Core Insights - Shenzhen has introduced new legislation aimed at promoting the innovation and development of the synthetic biology industry, addressing key challenges such as supply chain coordination and long approval cycles for new materials [1][5]. Group 1: Legislative Developments - The draft regulations consist of 30 articles and aim to tackle common pain points in the synthetic biology industry, including supply chain issues and the lengthy approval process for new materials [1]. - The regulations will be open for public consultation until June 13, indicating a collaborative approach to policy-making [1]. Group 2: Market Potential - According to McKinsey, the global bioeconomy is projected to reach $2 trillion to $4 trillion in the next 10-20 years, with the contribution of biological modification expected to rise to 30%-70% over time [1][4]. - In China, 40% of newly established synthetic biology companies in the past three years are concentrated in Shenzhen, highlighting the city's growing significance in this sector [1][5]. Group 3: Industry Collaboration - The draft regulations emphasize collaboration with national and provincial health departments to enhance the safety assessment of new food materials and additives [3]. - The regulations also aim to improve the efficiency of the approval process for new cosmetic ingredients, addressing existing challenges such as high costs and long timelines [2][3]. Group 4: Support Mechanisms - Shenzhen plans to establish specialized industrial parks for synthetic biology, providing necessary R&D and production facilities, as well as public technical services [5][6]. - The city will support higher education institutions in offering programs related to synthetic biology and encourage partnerships between academia and industry to cultivate talent [5][6]. Group 5: Financial Initiatives - The Shenzhen government will leverage investment funds to support small and medium-sized enterprises in the synthetic biology sector, enhancing access to financing for startups [6]. - A private equity fund focused on synthetic biology was established in Shenzhen with a scale of 1.5 billion yuan, and local banks have increased credit limits for startups in this field [6].

Core Viewpoint - The article highlights the significance of the New Fortune Gold Medal Secretary selection in the Chinese capital market, emphasizing the role of outstanding secretaries in enhancing corporate governance and investor relations, thus contributing to high-quality market development [1]. Company Overview - Jinbo Biological was established in 2008 and is headquartered in Taiyuan, Shanxi. It is recognized as a national-level specialized and innovative "little giant" enterprise and a key player in the synthetic biology industry chain in Shanxi Province. The company focuses on the research and industrialization of recombinant humanized collagen [5]. Key Achievements - Jinbo Biological became the first A-share listed company in China centered on "recombinant humanized collagen" after successfully completing its listing on July 20, 2023, on the Beijing Stock Exchange. This milestone serves as a model for the industrialization of original achievements by small and medium-sized enterprises in China [3]. - The company has received multiple approvals for innovative medical devices, including the first medical device product in China using new biological materials, and has established itself as a leader in the production of implant-grade medical devices globally [6][7]. Technological Breakthroughs - Jinbo Biological has achieved three core technological breakthroughs: 1. Safety breakthrough with a protein amino acid sequence highly consistent with natural collagen, showing strong biocompatibility and no immunogenic issues in over 2 million clinical applications [8]. 2. Effectiveness breakthrough with a clear 164.88° flexible triple helix structure, recognized by the international protein database [8]. 3. Application scenario breakthrough with high cell adhesion surpassing natural collagen, demonstrating excellent tissue repair characteristics across various fields [8]. Innovation Strategy - The company adheres to an "original innovation" strategy, having established six major technology platforms and multiple joint research platforms with prestigious institutions, covering the entire chain from basic research to clinical transformation and industrial implementation [9]. Role of the Secretary - The role of the board secretary is crucial in bridging the company and the capital market, requiring solid financial and legal knowledge, as well as excellent communication and coordination skills. The secretary's responsibilities include ensuring compliance, enhancing communication with regulatory bodies, investors, and media, and fostering a transparent public relations environment [14].

□ 本报记者徐维庆通讯员周健 "中试完成后，成品推向市场的成功率可达九成。"近日，站在已建成的全省最大合成生物蛋白制造中试 平台前，江苏创健医疗科技股份有限公司董事长钱松对合成生物的未来激情满满。 中间性试验，即小型生产模拟试验，是产品大规模量产前必不可少的环节。合成生物的中试，对相关企 业产品加速投向未来市场有着决定性作用。创健医疗投资1.2亿元，耗时两年时间打造了华东地区最大 的合成生物蛋白制造中试平台，集成陶瓷膜过滤、超滤、纳滤等多套纯化设备，实现酵母、大肠杆菌等 微生物发酵工艺开发与放大，同时结合AI实现全智能化生物制造，采用西门子自动化控制系统精准控 制工艺参数，每年可完成100—200批次工艺验证。 目前，创健医疗的中试平台已经开始承载核酸四面体、重组胶原蛋白等前沿项目工艺验证；同时，北京 市昌平合成生物制造技术创新中心、江南大学等高校科研院所与创健医疗联手，在常州启用部分先期科 研成果的中试，完成后将在全国范围内推广新品。 创健医疗在合成生物领域加码中试战略布局，有着更深层次的考量。以治疗阿尔茨海默病为例，在新药 开发中，基于DNA折纸技术构建，由4条单链DNA通过碱基互补配对原则，自发组装形成 ...

Group 1: Energy Storage Industry - Advanced Energy is one of the three leading industries in Changping District, with a focus on innovation in energy storage solutions [1] - Zhonghai Energy is developing iron-chromium flow batteries, which have a 90% water-based electrolyte, significantly reducing fire risks associated with traditional lithium-ion batteries [1][2] - The company has secured multiple billion-level orders and expects to achieve a revenue of 200 million yuan this year, with plans to establish three production bases across the country [2] Group 2: Pharmaceutical Industry - Innovent Biologics has received approval for its new BTK inhibitor, Oubatinib, for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), expanding its market potential [2][3] - The drug is also being explored for use in autoimmune diseases, with several clinical trials progressing to global Phase III [3] - The innovative design of Oubatinib allows for precise targeting of BTK proteins, minimizing side effects and enhancing safety for long-term use in autoimmune conditions [3] Group 3: Synthetic Biology and Advanced Manufacturing - The synthetic biology sector is emerging in Changping, with companies like Weiyuan Synthetic innovating in the production of rare sugars like allulose through engineered microorganisms [4] - The rapid growth of Weiyuan Synthetic is supported by public service platforms established by the district to aid startups in high-throughput screening and other essential services [4] - The private sector in Changping contributes significantly to the local economy, accounting for over 79.8% of large-scale enterprises and generating substantial tax revenue and employment [4]

（原标题：瑞德林刘建：重病之后，开启全新人生） 由"云上天泉"冠名播出的《Hi，老板》，最新一期约到了瑞德林董事长刘建。38岁那年，他的事业因为 重病按下暂停键。病愈后，带着对生命的全新敬畏，刘建选择创业，用6年的时间，带领瑞德林穿越死 亡谷，让公司成为合成生物领域的佼佼者。 点击观看视频：瑞德林刘建：重病之后，开启全新人生 以下是我们的对话，更多内容请关注"证券时报"官方视频号、抖音号《Hi，老板》专辑。 凌晨5点钟：属于自己的思考时间 刘建：我天性比较乐观，对生死看得比较开。 于德江：已经到生死这个维度了吗？ 刘建：当然，那叫恶性癌症。 于德江：2002年在兰大毕业之后，就来到了深圳，在一家药企工作，一路也做到了高层，什么原因要毅 然决然地去辞职创业？ 刘建：其实我是喜欢挑战的人，在上市公司，我也负责过一个公司，我们当初花十多个亿，收了一家公 司。我做总经理来做投后管理，它的企业在西北。相对来说，管理比较落后，把这样的一个企业，融入 到这种相对来说节奏比较快、管理要求比较高的一个体系，其实难度很大，所以那时候压力也大、应酬 也多，加上作息不规律、睡眠的时间不够，所以后来到了2015年、2016年的时候就生 ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 4月26日，第三届中国（安徽）科交会专项活动——合成生物平台建设和科技招商专项活动在合肥举办。 在重大项目签约环节，合肥高新区管委会、芜湖三山经开区管委会等地方政府单位与上海凯赛生物、深圳华大基因等企业集中签约了"生物基复合材料新 能源结构件研发制造项目"等5项"双招双引"重点项目， 累计投资达11.8亿元 。 其中，芜湖市三山经开区与 福莱 明生物 签约" 重组胶原蛋白和类胶原蛋白产品研发产业化项目 "；合肥市庐阳区与 华大基因 农业 签约" 华大生物农业 应用研究院建设和科技成果产业化项目 "； 安徽科宝生物 与中科院合肥物质研究院合作签约" 名贵中药材体培牛黄及其关键原料胆红素生物制造产业化 核心技术攻关 "项目，合肥高新区与 凯赛生物 签约" 生物基复合材料新能源结构件研发制造项目 "。 此外，由中国科学技术大学副校长周丛照、安徽师范大学常务副校长熊宇杰等专家学者发起的 安徽省合成生物学会 （筹）组建启动仪式也在当天举行。 资料来源： 添加微信请备注 ...

作为成都科技创新的主阵地，成都高新区是全国首批 "创建世界一流高科技园区"试点之一，经 过3 0余年的奋斗，已成为全国发展质量效益最好、科技创新实力最强、高科技企业和创新型成 长型企业密度最高的高新区之一。 4月2 5日，2 0 2 5年成都高新区产业基金协同发展大会在成都高新区菁蓉汇举办。 大会现场，成都高新区立足区域产业基础，正式发布产业发展图谱，建立 " 3+6+6 "现代化产业 体系，即3大特色优势产业（电子信息、医药健康、数字经济），6大战略性新兴产业（人工智 能、低空经济、商业航天、网络空间安全、先进装备和先进能源），6大未来产业（人形机器 人、细胞与基因治疗、合成生物、新型储能（含新型材料方向）、量子科技、脑机接口）。 据悉，截至目前， 成都高新区已出资组建基金 1 5 4只，总规模超3 2 3 6亿元，形成了中西部产 业园区规模最大的产业基金集群 ，并构建起涵盖 "资助—种子—天使—创投—产投—并购"的 全生命周期资本支持服务体系，实现电子信息、医药健康、数字经济等优势产业全覆盖。 大会现场，成都高新区策源资本与中金资本、中信建投资本、工银投资、建信金投、环投资本 等 11家机构进行了产业基金 ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 4月22日晚间， 华恒生物（688639） 发布2024年年报。 2024年，华恒生物实现 营业收入21.78亿元 ，同比增长12.37%； 归母净利润为1.90亿元 ，同比下降57.80%；基本每股收益0.82元。 | 主要会计数据 | 2024年 | 2023年 | 本期比上年同 | 2022年 | | --- | --- | --- | --- | --- | | | | | 期增减(%) | | | 营业收入 | 2, 177, 940, 839. 23 | 1, 938, 268, 117. 78 | 12. 37 | 1, 418, 651, 882. 92 | | 归属于上市公司 | 189, 518, 896. 19 | 449, 061, 466. 72 | -57.80 | 320, 029, 449. 81 | | 股东的净利润 | | | | | | 归属于上市公司 股东的扣除非经 | 177.240.619.67 | 438.093 ...

Core Insights - The National Bio-Manufacturing Industry Innovation Center and Jianfa New Mei Synthetic Biology Industrial Park have established a strategic partnership to create an innovation hub and industrial transformation base in China's synthetic biology sector [1][2]. Group 1: Strategic Collaboration - The National Bio-Manufacturing Industry Innovation Center is the first national-level innovation platform in the bio-manufacturing field in China, aimed at enhancing key common technology collaboration and building an innovative ecosystem [1]. - Jianfa New Mei Synthetic Biology Industrial Park is positioned as a high-end life sciences industrial park focusing on bio-materials and bio-foods, with significant support policies and a complete hardware setup [1][2]. Group 2: Industry Development - The Guangming District has attracted 123 synthetic biology companies with a total valuation of nearly 40 billion yuan, generating an annual output value of over 4 billion yuan in the synthetic biology industry cluster [2]. - A planned investment of 500 million yuan will support industry innovation, alongside the establishment of a 1.5 billion yuan Shenzhen Synthetic Biology Industry Fund to enhance the local synthetic biology ecosystem [2]. Group 3: Future Prospects - The strategic collaboration aims to link technology, capital, and market resources, facilitating the transition of the synthetic biology industry from technological breakthroughs to commercialization [2]. - The partnership is expected to help companies gain a competitive edge in strategic fields such as healthcare and green energy, contributing to the global bio-economy [2].